“Crouch” Proposal Targets Nearly $90 Billion in Savings Through Health Care Fraud Crackdown
Key Facts
On November 16, 2026, the Centers for Medicare & Medicaid Services issued the “Crouch” proposal to combat fraud, waste and abuse in Medicare, Medicaid, CHIP and the health insurance marketplace. The agency estimated that the proposal could generate nearly $90 billion in federal savings during 2027–2036, against estimated costs of about $378.51 million over the same period. The estimates place efforts to curb improper payments at the heart of the plan, with a prominent focus on auditing Medicare Advantage payments. But the figures are CMS estimates for the proposal, and the text remains open for public comment. A 9% drop in Humana shares during the session when the news broke could not be verified through a credible source that could be accessed.
The proposal includes reforms to risk-adjustment audits in Medicare Advantage, including applying extrapolation to audits for plan years beginning in 2018. Extrapolation means using audit findings to estimate overpayments on a broader scale, rather than limiting recovery to cases directly examined. The Federal Register said the RADV program oversees, according to the agency’s estimate, $21 billion in annual overpayments resulting from improper inflation of beneficiaries’ risk scores. This estimate links the audit process to large sums that CMS says are paid above the amounts due. Expanding the scope of audits is one of the proposal’s main regulatory pillars.
The text also addresses how Medicare Advantage companies and Part D plan sponsors handle suspected fraud. It proposes making referrals of confirmed or suspected cases of fraud, waste or abuse a mandatory reporting requirement. It also proposes expanding reporting on payment suspensions when they are prompted by suspected fraud. CMS cites inadequate reporting to justify the change: the Federal Register said that only 46% of Medicare Part C and Part D plan contracts reported such referrals in calendar year 2025. That is less than half of contracts, according to the agency, and places referral and reporting requirements within the scope of the proposal.
The plan follows Humana’s announcement of its third-quarter 2026 results, with earnings of $1.33 per share under generally accepted accounting principles and an adjusted loss of $0.70 per share. The results provide recent financial context for the company as CMS proposes changes affecting Medicare Advantage audits. However, the federal estimates of savings and costs do not by themselves determine the final financial impact on Humana or other insurers. Nor do the available materials establish that the company’s share-price movement was tied to specific earnings or valuation expectations. The proposal therefore remains a regulatory development under review until the comment period ends and any final rule is issued.
Humana is scheduled to hold a virtual investor update on December 10, 2026, to review progress against the framework it presented at its 2025 Investor Day and the initiatives it expects to support earnings growth through 2028. The event comes after CMS announced the proposal, but concerns the company’s plan and initiatives, not a final decision on regulatory rules. The public comment period on the “Crouch” proposal closes on January 19, 2027. After that, the next regulatory steps will depend on CMS’s review of the comments and its decisions on the proposed text.